24/7 Market News Snapshot 19 December, 2024 – Personalis, Inc. Common Stock (NASDAQ:PSNL)

December 19, 2024

DENVER, Colo., 19 December, 2024 (247marketnews.com) – (NASDAQ:PSNL) are discussed in this article.
Personalis, Inc. (PSNL) is garnering significant attention on the stock market as shares opened at $3.81 and soared to $4.519, reflecting a remarkable increase of approximately 26.94%. Following a previous closing price of $3.560, this surge demonstrates robust market confidence, with current trading volume reaching 1.17 million. Enthusiasm among investors highlights the company’s potential as it navigates a pivotal moment in its market journey.

The recent developments at Personalis extend beyond market performance. The firm has announced substantial advancements in its strategic partnerships with industry leaders Merck and Moderna, focused on revolutionizing cancer care through innovative personalized therapies. In a landmark investment, Merck has committed $50 million to Personalis by purchasing common stock at $3.56 per share, raising its beneficial ownership interest to approximately 16.5%. This investment underscores Merck’s confidence in Personalis’ capabilities and the enduring collaboration that has flourished since the V940/mRNA-4157 clinical development program commenced.

Moderna’s continued alliance with Personalis enables the latter to leverage its ImmunoID NeXT Platform® for the development of investigational individualized neoantigen therapy (INT) targeted at cancer treatment. This multi-year collaboration emphasizes the critical role of Personalis’ advanced tumor-profiling technology in improving cancer management strategies.

Chris Hall, CEO of Personalis, voiced excitement over these strategic collaborations, asserting that individualized therapies have the potential to revolutionize cancer treatment. He emphasized that the deepening partnership with Merck and Moderna will enhance Personalis’ ability to deliver effective cancer care.

As Personalis continues to lead in personalized cancer management, its cutting-edge technology is set to significantly influence treatment pathways, guiding patients toward more effective and tailored therapeutic options. The ongoing collaborations exemplify Personalis’ strategic vision, reinforcing its commitment to advancing precision oncology globally.

Related news for (PSNL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.